Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28612059
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Investig Clin Urol
2017[Jun]; 58
(Suppl 1
): S38-S45
PMID28612059
show ga
Since the U.S. Food and Drug Administration approved dextranomer/hyaluronic acid
copolymer (Deflux) for the treatment of vesicoureteral reflux, endoscopic
injection therapy using Deflux has become a popular alternative to open surgery
and continuous antibiotic prophylaxis. Endoscopic correction with Deflux is
minimally invasive, well tolerated, and provides cure rates approaching those of
open surgery (i.e., approximately 80% in several studies). However, in recent
years a less stringent approach to evaluating urinary tract infections (UTIs) and
concerns about long-term efficacy and complications associated with endoscopic
injection have limited the use of this therapy. In addition, there is little
evidence supporting the efficacy of endoscopic injection therapy in preventing
UTIs and vesicoureteral reflux-related renal scarring. In this report, we
reviewed the current literature regarding endoscopic injection therapy and
provided an updated overview of this topic.
free
free
free
